As no previous studies have investigated in vivo the combination of a microtubule disruptor and 2DG in breast and prostate cancer, the efficacy of STX140 and 2DG was assessed in the MCF-7 (ER-positive, breast) and LNCaP (AR-positive, prostate) xenograft models. This evidence concerns the gene AR and prostate carcinoma.